Dr. Ciezki on Common Advanced Disease Sites in Patients

Jay Ciezki, MD
Published: Thursday, Dec 24, 2015



Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

In clinical practice, Ciezki says he has noticed more patients presenting with advanced disease over the last 2 to 3 years. To gain a deeper understanding of this occurrence, Ciezki and other researchers examined a 20-year database of patients and the stage they presented with.

As a result of the query, Ciezki concluded that more patients presented with advanced stage disease in the last 2 to 3 years compared with patient visits from earlier years. The tumor type that was found to be most commonly presented as advanced was prostate cancer. This is interesting, Ciezki says, because prostate cancer is very screenable, treatable, and curable.



Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

In clinical practice, Ciezki says he has noticed more patients presenting with advanced disease over the last 2 to 3 years. To gain a deeper understanding of this occurrence, Ciezki and other researchers examined a 20-year database of patients and the stage they presented with.

As a result of the query, Ciezki concluded that more patients presented with advanced stage disease in the last 2 to 3 years compared with patient visits from earlier years. The tumor type that was found to be most commonly presented as advanced was prostate cancer. This is interesting, Ciezki says, because prostate cancer is very screenable, treatable, and curable.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x